News
HanchorBio Prices IPO at NT$120 Ahead of Innovation Board Listing on May 29
HanchorBio announced the completion of bookbuilding for its initial public offering on the Taiwan Innovation Board. The offering price has been set at NT$120 per share. HanchorBio is expected to list on the Taiwan Innovation Board on May 29, 2026.
May 26, 2026
Read more
HanchorBio Reports First Licensing Revenue and Outlines 2026 Clinical and Business Development Priorities
HanchorBio today announced that its 2026 Annual General Meeting was successfully held on May 21, 2026, in Taipei, Taiwan. Shareholders approved all proposed resolutions, including the 2025 business report, financial statements, and loss offset proposal.
May 21, 2026
Read more
HanchorBio Announces First Confirmed Partial Response in Colorectal Cancer Cohort of Ongoing HCB101-201 Combination Study
HanchorBio announced the first confirmed partial response (PR) in the colorectal cancer (CRC) cohort of its ongoing clinical study evaluating HCB101 in combination with standard-of-care regimens (NCT06771622).
May 18, 2026
Read more
HanchorBio Expands HCB206 Development into Autoimmune Diseases and Advances Key Preclinical Studies
HanchorBio announced that its internally developed dual-target fusion protein candidate, HCB206, has demonstrated therapeutic potential in preclinical studies across both oncology and autoimmune disease models.
May 11, 2026
Read more
HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
HanchorBio announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
May 08, 2026
Read more
HanchorBio Launches HCB101 Mechanism Collaboration Study with the Institute of Tsinghua University, Hebei
HanchorBio started a research collaboration with the Institute of Tsinghua University, Hebei, to further characterize the antitumor mechanisms and translational biology of HCB101, the Company’s AI-guided, structurally engineered, Fc-based fusion protein targeting the CD47-SIRPα axis.
May 05, 2026
Read more
HanchorBio Highlights Next Generation Combination Backbone Potential, Platform Expansion Beyond Oncology, and Tri-specific Mechanistic Progress at TJCC 2026
HanchorBio presented at the 30th Taiwan Joint Cancer Conference (TJCC 2026). Across a keynote lecture and the company symposium, HanchorBio highlighted clinical and translational data supporting HCB101 as a clinically versatile innate immune backbone and presented a working mechanism framework for its next-generation tri-specific program, HCB301.
May 04, 2026
Read more
HanchorBio and NYCU Launch AI-Enabled Drug Discovery Collaboration to Advance Next-Generation Biologics
HanchorBio started a research collaboration with the College of Engineering Bioscience at National Yang Ming Chiao Tung University (NYCU) to advance AI-enabled biologics discovery.
Apr 29, 2026
Read more
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
Apr 24, 2026
Read more
HanchorBio Selects Bloomberg to Strengthen its Strategic Intelligence Across Drug Development and Global Biopharma
HanchorBio announced it has selected Bloomberg to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities.
Apr 24, 2026
Read more